One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs that's proven to be both efficacious and safe in clinical studies and in the real world. You might be familiar with the top sellers, such as Eli Lilly's Zepbound or Novo Nordisk's Wegovy -- they've made headlines as demand for them soared.In fact, demand for these drugs has been so strong that it even surpassed supply until the drugmakers took action to scale up manufacturing capacit ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily gain of 0.88%. At the same time, the Dow added 1.24%, and the tech-heavy Nasdaq gained 0.65%.The the stock of company has fallen by 22.85% in the past month, lagging the Medical sector's loss of 0.32% and the S&P 500's gain of 1.17%.Analysts and investors alike will be keeping a close eye on the performance of Viking ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polyp ...

This is a high-risk, high-reward stock.In this video, I will cover the recent updates regarding Viking Therapeutics (VKTX 0.56%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Jan. 3, 2025. The video was published on Jan. 4, 2025. ...

Market Dynamics - Viking Therapeutics' share price declined by 24% in December 2024 due to intensified competition in the pharmaceutical market [1] - Merck entered into a licensing deal with Hansoh Pharma for an investigational weight-loss drug HS-10535, posing a threat to Viking's VK2735 program [3] - The weight-loss drug market is highly lucrative with only two GLP-1 drugs approved in the US, indicating significant growth potential [6] Competitive Landscape - Merck secured exclusive global licensing rights to HS-10535, committing $112 million upfront and up to $1.9 billion in milestone payments and royalties [5] - Viking's VK2735, an oral obesity drug, is relatively advanced in development and has shown promising results in clinical trials [3][8] - VK2735 has a competitive advantage over injectable treatments like Novo Nordisk's Wegovy and Eli Lilly's Zepbound [4] Development Progress - HS-10535 is still in development and its efficacy remains uncertain, while VK2735 is closer to commercialization [7][8] - Viking's VK2735 is positioned as a potential go-to treatment due to its oral administration format [8]

It's been an excellent year for Viking Therapeutics (VKTX 2.19%), a mid-cap biotech company. Thanks to impressive mid-stage clinical results, its stock skyrocketed in February. And although it's down from the all-time highs it hit earlier this year, it remains one of the better performers in the industry over the past 12 months.However, Viking's shares recently dropped massively -- by more than 10% -- in one day. And the stock is down 24% in the past month. What exactly caused this recent decline? Should in ...

The weight-loss biotech Viking Therapeutics (VKTX 1.83%) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (MRK -1.48%).Given that Viking doesn't yet have any products approved for sale, is this the start of the end, or just a rough bump in the road?The market's fears are overblown, but not ungroundedFirst, let's get to the bottom of what Merck did to provoke Viking's stock into tumbling so much and so quickly.Merck just signed a licensing deal with a ...

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (VKTX 1.83%) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence, the biotech's share price fell by just over 10% over the period as a result.Merck makes a moveThat news hit the headlines on Wednesday, with global pharmaceutical company Merck announcing that it had entered into an exclusive worldwide licensing arrangement for a GLP-1 obesity drug currently in development ...

Shares of Viking Therapeutics (VKTX) lost 18% yesterday after pharma giant Merck (MRK) announced its foray into the obesity space. On Wednesday, Merck announced that it has secured a licensing deal for China-based Hansoh Pharma's investigational weight-loss drug. More on MRK's Drug Deal Per the terms of the deal, Merck will obtain exclusive rights to develop and market HS-10535, a preclinical oral small-molecule GLP-1 receptor agonist targeting metabolic disorders, including obesity. Hansoh will receive an ...

Viking Therapeutics Inc. VKTX is nearing a pivotal moment as its stock hovers just above a potential death cross.This ominous technical pattern, where the 50-day moving average moves below the 200-day moving average, is often seen as a bearish signal. While not confirmed yet, the trajectory suggests growing pressure on the stock, which has struggled in recent months despite earlier rallies. Chart created using Benzinga ProRead Also: Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss DrugsVKTX ...